A substantial number of clinical trials are currently exploring the applicability of immunotherapy for the treatment of HNSCC, with primary focus on immune checkpoint blockade via CTLA-4 and PD1 [12]. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.